Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC

Nov 7, 20244 min read

Dragonfly Announces Clinical Collaboration to Evaluate DF9001 in Combination with KEYTRUDA® in Patients with Solid Tumors

May 21, 20242 min read

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303

Mar 5, 20242 min read

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications

Feb 15, 20242 min read

Dragonfly Initiates Phase 1/1b Study of its IL-2 Immunotherapy

Dec 5, 20232 min read

One R.I. man’s battle with Stage 4 colon cancer

Aug 8, 20235 min read